What does Natera do?
Natera is a rapidly growing genetic testing and diagnostics company with proprietary bioinformatics and molecular technology. Natera’s team of PhDs and engineers is dedicated to refining novel molecular genome assays and complex statistical algorithms to determine the likelihood of a wide range of serious genetic conditions with best-in-class accuracy and coverage. Natera’s goal is to change the management of genetic disease worldwide, giving patients and providers essential health information.

When was Natera founded?
Natera was founded in 2003.

How many employees does Natera have?
As of March 31, 2015, Natera had 674 employees.

When did Natera go public and what was the offering price?
Natera went public on July 1, 2015 at $18.00 per share.

Who were the underwriters in the IPO?
Our underwriters were Morgan Stanley & Co. LLC, Cowen and Company, LLC, Piper Jaffray & Co., Robert W. Baird & Co. Incorporated, and Wedbush Securities Inc.

How can I obtain a copy of the final prospectus?
All of Natera’s financial publications are available here.

Where does Natera’s stock trade?
Natera is listed on the Nasdaq Global Select Market under the ticker symbol NTRA.

How can I find out the current and historical prices of NTRA?
The current and historical stock price of NTRA can be found here. For more current information and historical prices, visit our Stock Information pages.

Who is Natera’s transfer agent?
Computershare Trust Company, N.A.
250 Royall Street
Canton, MA 02021
(800) 662-7232

What is Natera’s CUSIP number?
The CUSIP number for Natera’s common stock is 632307104.

Does Natera pay a dividend on its common stock?
Natera has never declared or paid any cash dividend on its capital stock and does not anticipate paying any dividends in the foreseeable future.

When does Natera’s fiscal year end?
Natera’s fiscal year ends December 31.

Who is Natera’s independent auditor?
Ernst & Young LLP.

How can I contact investor relations for Natera?
Please visit our Contact page.

Shareholder Tools